A variety of therapeutic agents such as noncoding RNAs, natural products, and clinical therapeutics aiming to restore PTEN expression/activity have showed great potential in the tested lung diseases in vitro and in vivo, but their exact mechanisms of action have not been fully elucidated. This evidence concerns the gene PTEN and lung disorder.